Limited cell dose hampers wider use of cord blood transplantation (CBT). By depleting plasma but not RBC during processing, nucleated cell (NC) loss is reduced to <0.1% which increases significantly the proportion of high cell dose products—3-fold for products with NC ≥200 × 10 7 . Clinical outcome for plasma depleted (PD) CBT was previously unavailable. A retrospective audited analysis was performed on 118 PD CBT, with mean and median NC doses of 7.6 × 10 7 /kg and 5.6 × 10 7 /kg, respectively, for this mostly pediatric population. The median times to engraftment and engraftment rates for ANC 500 and platelet 20K were 22 and 50 days, respectively, and 90% ± 3% and 77% ± 5%, respectively. The incidences of grade III-IV acute graft-versus-host disease (aGVHD) and extensive chronic GVHD (cGVHD) were 13% ± 4% and 17% ± 6%, respectively. Relapse rate for malignancies was 25% ± 6% and 100-day treatment-related mortality (TRM) was 16% ± 3%. With a median follow-up of 557 days, the 1-year overall survival and relapse-free survival are 65% ± 5% and 51% ± 6%, respectively. These results demonstrate that PD CBT is safe and effective, and that eliminating RBC reduction or depletion improves cell recovery during CB processing, resulting in a larger proportion of the inventory with high NC number.